{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-055679","form_type":"8-K","ticker":"TOVX","cik":"0000894158","company_name":"Theriva Biologics, Inc.","filed_at":"2026-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.893659+00:00","generated_at":"2026-05-14T23:43:20.741333+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Theriva Biologics reports Q1 2026 net loss $2.0M, FDA agrees to Phase 3 design for VCN-01 in PDAC","bullets":["Cash and cash equivalents $14.4M as of March 31, 2026; cash runway into Q1 2027.","FDA alignment on Phase 3 trial design for VCN-01 plus gemcitabine/nab-paclitaxel in metastatic PDAC.","New VIRAGE Phase 2b data at AACR 2026 shows improved OS and PFS across subgroups including liver metastases.","Compassionate use of VCN-01 in retinoblastoma started; Phase 2/3 trial expected first patient Dec 2026.","R&D expenses fell 88% to $355K as VIRAGE trial completed; G&A rose 43% to $2.1M."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-055679","json":"https://secwatch.observer/filing/0001104659-26-055679.json","markdown":"https://secwatch.observer/filing/0001104659-26-055679.md","text":"https://secwatch.observer/filing/0001104659-26-055679.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/894158/000110465926055679/0001104659-26-055679-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/894158/000110465926055679/tm2613605d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T23:43:20.741333+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"462832afab8182407513e2f6c88570c27eb3972f","claim":"Theriva Biologics, Inc. reported financial results for quarter ended March 31, 2026.","evidence_excerpt":"On May 5, 2026, Theriva Biologics, Inc., a Nevada corporation (the “Company”), issued a press release that included financial information for its quarter ended March 31, 2026.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/894158/000110465926055679/0001104659-26-055679-index.htm","confidence":0.8,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended March 31, 2026"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}